유리체강내 Fluocinolone Acetonide Implant 삽입 후 호전된 베체트 포도막염 1예A Case of Refractory Behçet’s Uveitis Improving after Insertion of Fluocinolone Acetonide Implant
- Other Titles
- A Case of Refractory Behçet’s Uveitis Improving after Insertion of Fluocinolone Acetonide Implant
- Authors
- 김윤성; 최정란; 김석원; 김현숙
- Issue Date
- 2013
- Publisher
- 대한류마티스학회
- Keywords
- Behçet’s disease; Uveitis; Fluocinolone acetonide implant
- Citation
- 대한류마티스학회지, v.20, no.2, pp 123 - 126
- Pages
- 4
- Journal Title
- 대한류마티스학회지
- Volume
- 20
- Number
- 2
- Start Page
- 123
- End Page
- 126
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/14444
- ISSN
- 2093-940X
2233-4718
- Abstract
- Behçet’s disease (BD) is systemic vasculitis that can manifest severely debilitating. Despite the understanding mechanisms of overall BD, there are remains many questions in various critical manifestations and treatments. The ocular manifestation is characterized by a prototype of chronic relapsing and persistent uveitis. The main treatment is topical corticosteroid, and topical nonsteroidal anti-inflammatory drugs in mild uveitis. The recurrent and severe uveitis could be treated with ocular corticosteroid injections, and systemic corticosteroid for inducing long-lasting suppression of the inflammation. Systemic corticosteroids should rapidly be tapered within weeks for avoiding side effects. Recent advances have led to the development of sustained-release corticosteroid devices using different corticosteroids. We present a case of 67-year-old woman who received a fluocinolone acetonide implant for recurrent Behçet’s uveitis. She was successfully treated with implant and the uveitis became quiescent within a month.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/14444)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.